PI-0824

Phase 1Small molecule

PPeptimmune

PI-0824 is one of 22 small molecule programs targeting Pemphigus Vulgaris. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pemphigus VulgarisActive, not recruiting

Pemphigus VulgarisPhase 1

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Pemphigus Vulgaris

#DrugCompanyPhaseTrials

Cellcept

Roche

Approved

2 2

Orencia

Bristol-Myers Squibb

Approved

1 3

Decadron

AAspen Global Incorporated

Kesimpta

3 5

Rituxan

Roche

Phase 3

1 6

Kenalog

BBausch Health Americas, Inc.

Phase 3

1 7

Prednisone/prednisolone

Roche

Phase 3

1 8

Acetaminophen/paracetamol

Roche

Phase 3

1 9

Antihistamine

Arrowhead Pharmaceuticals

Phase 3

1 10

Avlosulfon

AAlmirall, S.A.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pemphigus Vulgaris1 trial

Safety Study of PI-0824 to Treat Pemphigus Vulgaris

Completed·PPeptimmune·Phase 1·NCT00063752·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PI-0824. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PI-0824 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PI-0824. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peptimmune company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPeptimmune

PI-0824

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pemphigus Vulgaris1 trial

References

Drug Info

Quick Facts

Related News